Zobrazeno 1 - 10
of 20
pro vyhledávání: '"V. Vihervaara"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Saku Torvinen, Jonna Salonen, Anu Marttila, Tatu Miettinen, Klaus Tamminen, Melissa Bauer, Jari Jokelainen, V. Vihervaara
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e224-e225
Publikováno v:
Journal of medical economics. 22(4)
To estimate the drug administration, travelling, and productivity costs associated with infusion or subcutaneous proteasome inhibitor (PI) treatments (specifically carfilzomib and bortezomib) for multiple myeloma (MM) patients in Finland.Price tariff
Autor:
Saku Torvinen, Anu Marttila, Melissa Bauer, Jonna Salonen, Tatu Miettinen, Klaus Tamminen, V. Vihervaara, Jari Jokelainen
Publikováno v:
International Journal of Clinical and Experimental Medical Sciences. 7:21
Multiple myeloma (MM) is one of the most prevalent hematologic cancers. Treatments of MM have been improved by availability of novel therapies but require regular hospital visits and intense patient follow-up. In this real-world study, patient charac
Autor:
Saku Torvinen, J. Salonen, V. Vihervaara, T. Miettinen, M. Bauer, A. Rasanen, K. Tamminen, J. Jokelainen
Publikováno v:
Value in Health. 22:S466
Autor:
V. Vihervaara, Saku Torvinen, H. Loponen, K. Tamminen, T. Ylisaukko-oja, S. Ylä-Viteli, M. Silvoniemi
Publikováno v:
Value in Health. 21:S34
Publikováno v:
Value in Health. 20:A558
Publikováno v:
Value in Health. 16(7)
Publikováno v:
Clinical therapeutics. 34(4)
Background The cost-effectiveness analyses of follicular lymphoma (FL) treatments have focused on the second-line rituximab maintenance in patients with relapsed FL. The assessment of full FL treatment chain has been lacking. Objective The aim of thi
Publikováno v:
Journal of medical economics. 15(2)
The aim of this study was to assess the cost-utility and value of reducing the uncertainty associated with the decision to use first-line biologic treatment (bDMARD) after the failure of one or more traditional drugs (tDMARD) in moderate-to-severe rh